Atlas Venture has been running for over 30 years and is one of the world's leading biotech-only VCs. The firm operates a two-fund model: Fund XIV ($450M, closed December 2024) for seed and Series A, and Opportunity Fund III ($400M, closed September 2025) for growth-stage follow-on.
The company-building track record is substantial — 78 startups launched through the incubator, with 42 IPOs and 37 M...
Chicago, United States
Boston, United States
Santa Monica, United States
Cambridge, United Kingdom
San Francisco, United States
Cambridge, United States